MA55491A - Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations - Google Patents

Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations

Info

Publication number
MA55491A
MA55491A MA055491A MA55491A MA55491A MA 55491 A MA55491 A MA 55491A MA 055491 A MA055491 A MA 055491A MA 55491 A MA55491 A MA 55491A MA 55491 A MA55491 A MA 55491A
Authority
MA
Morocco
Prior art keywords
pyroglutamate
amyloid beta
beta antibodies
antibodies
amyloid
Prior art date
Application number
MA055491A
Other languages
English (en)
Inventor
Wilson Edwards
Rajkumar Ganesan
Chichi Huang
Porte Sherry La
Jinquan Luo
Marc Mercken
Sanjaya Singh
Broeck Bianca Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA55491A publication Critical patent/MA55491A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055491A 2019-03-26 2020-03-25 Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations MA55491A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962823785P 2019-03-26 2019-03-26

Publications (1)

Publication Number Publication Date
MA55491A true MA55491A (fr) 2022-02-09

Family

ID=70008544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055491A MA55491A (fr) 2019-03-26 2020-03-25 Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations

Country Status (22)

Country Link
US (4) US11236155B2 (fr)
EP (1) EP3946603A1 (fr)
JP (2) JP7617848B2 (fr)
KR (1) KR20210143858A (fr)
CN (2) CN113891746B (fr)
AU (1) AU2020245031B2 (fr)
BR (1) BR112021019107A2 (fr)
CA (1) CA3134785A1 (fr)
CL (2) CL2021002473A1 (fr)
CO (1) CO2021014028A2 (fr)
CR (1) CR20210492A (fr)
DO (1) DOP2021000199A (fr)
EA (1) EA202192606A1 (fr)
EC (1) ECSP21079184A (fr)
IL (1) IL286634A (fr)
JO (1) JOP20210265A1 (fr)
MA (1) MA55491A (fr)
MX (1) MX2021011715A (fr)
PE (1) PE20212266A1 (fr)
PH (1) PH12021552334A1 (fr)
SG (1) SG11202110504XA (fr)
WO (1) WO2020193644A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (fr) 2019-01-30 2020-08-06 Immutics, Inc. Anticorps anti-gal3 et leurs utilisations
JOP20210265A1 (ar) * 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
EP4157338A4 (fr) 2020-05-26 2024-11-13 TrueBinding, Inc. Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
CN118355027A (zh) * 2021-10-28 2024-07-16 艾伯维公司 抗淀粉样蛋白β抗体及其使用方法
CN119173531A (zh) 2022-03-11 2024-12-20 詹森药业有限公司 多特异性抗体及其用途
AU2023232448A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
CA3254442A1 (fr) * 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Anticorps multispécifiques et leurs utilisations
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (fr) 2024-06-20 2025-12-26 Bioarctic Ab Molécule de liaison bispécifique
CN118459582B (zh) * 2024-07-11 2024-11-15 苏州近岸蛋白质科技股份有限公司 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2321348A2 (fr) 2008-07-09 2011-05-18 University of Zürich Procédé d'activation de la neurogenèse
WO2010009987A2 (fr) 2008-07-21 2010-01-28 Probiodrug Ag Dosage d'anticorps de diagnostic
WO2011016238A1 (fr) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Anticorps qui se lient spécifiquement à des bêta-oligomères et utilisation de ceux-ci
MA34057B1 (fr) * 2010-02-23 2013-03-05 Genentech Inc Compositions et methodes pour le diagnostic et le traitement d'une tumeur
WO2011151076A2 (fr) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Anticorps monoclonaux ciblant des oligomères aβ
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
WO2012021475A2 (fr) 2010-08-12 2012-02-16 Eli Lilly And Company ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
EP2511296A1 (fr) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Anticorps, kit et procédé pour déterminer des peptides amyloïdes
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2015175769A1 (fr) 2014-05-15 2015-11-19 Biogen Ma Inc. Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques
WO2015191825A1 (fr) 2014-06-13 2015-12-17 Biogen Ma Inc. Méthodes pour la détection et la mesure de la protéine beta amyloïde dans des échantillons biologiques
WO2016020880A2 (fr) * 2014-08-07 2016-02-11 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
CA2992386A1 (fr) 2015-07-16 2017-01-19 Probiodrug Ag Anticorps humanises
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107774A1 (es) 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
EP3249388A1 (fr) 2016-05-23 2017-11-29 Raman Health Technologies, S.L Procédé de diagnostic de la maladie d'alzheimer
CN114796481A (zh) 2016-06-07 2022-07-29 生物基因国际神经科学有限责任公司 治疗阿尔茨海默病的方法
CA3032692A1 (fr) 2016-08-09 2018-02-15 Eli Lilly And Company Polytherapie a base d'anticorps pour le traitement de maladies neurodegeneratives
AR110470A1 (es) 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI789644B (zh) 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
KR102784294B1 (ko) * 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
CN113164777B (zh) * 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
JOP20210265A1 (ar) * 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها

Also Published As

Publication number Publication date
KR20210143858A (ko) 2021-11-29
CL2021002473A1 (es) 2022-04-22
CN113891746B (zh) 2025-05-06
AU2020245031A1 (en) 2021-10-21
PH12021552334A1 (en) 2022-07-04
CN120468431A (zh) 2025-08-12
JP7837375B2 (ja) 2026-03-30
CL2022002670A1 (es) 2023-03-31
PE20212266A1 (es) 2021-11-30
MX2021011715A (es) 2021-12-10
SG11202110504XA (en) 2021-10-28
CR20210492A (es) 2021-11-19
IL286634A (en) 2021-10-31
JP7617848B2 (ja) 2025-01-20
US11236155B2 (en) 2022-02-01
JOP20210265A1 (ar) 2023-01-30
DOP2021000199A (es) 2022-07-15
EP3946603A1 (fr) 2022-02-09
CN113891746A (zh) 2022-01-04
JP2022526528A (ja) 2022-05-25
CO2021014028A2 (es) 2021-10-29
BR112021019107A2 (pt) 2021-11-30
EA202192606A1 (ru) 2022-01-24
JP2025000645A (ja) 2025-01-07
CA3134785A1 (fr) 2020-10-01
WO2020193644A1 (fr) 2020-10-01
ECSP21079184A (es) 2021-11-30
AU2020245031B2 (en) 2026-04-09
US20220106387A1 (en) 2022-04-07
US20200308261A1 (en) 2020-10-01
US20250320286A1 (en) 2025-10-16
US20220177560A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
MA55491A (fr) Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3958910A4 (fr) Conjugués anticorps anti-cd45-médicaments et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
EP3849608A4 (fr) Nouveaux anticorps anti-lilrb4 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
EP3908603A4 (fr) Anticorps muc1* antivariables et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
EP3894440A4 (fr) Anticorps anti-il-27 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations
EP4010368A4 (fr) Anticorps anti-nampt et leurs utilisations
MA52094A (fr) Anticorps anti-il-27 et leurs utilisations
MA55613A (fr) Anticorps anti-intégrine et leurs utilisations
EP3755716A4 (fr) Anticorps anti-pd-1 et leurs utilisations
EP4081548A4 (fr) Anticorps monoclonaux anti-sirp? et leurs utilisations
EP3883969A4 (fr) Anticorps anti-pd-1 et leurs utilisations